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Abstract
Background: The aim of the thesis is to improve radiation plans of patients with locally advanced, unresectable
pancreatic cancer by using carbon ion and proton beams.
Patients and methods: Using the treatment planning system Syngo RT Planning (Siemens, Erlangen, Germany) a total
of 50 treatment plans have been created for five patients with the dose schedule 15 × 3 Gy(RBE). With reference to the
anatomy, five field configurations were considered to be relevant. The plans were analyzed with respect to dose
distribution and individual anatomy, and compared using a customized index.
Results: Within the index the three-field configurations yielded the best results, though with a high variety of score
points (field setup 5, carbon ion: median 74 (range 48–101)). The maximum dose in the myelon is low (e.g. case 3,
carbon ion: 21.5 Gy(RBE)). A single posterior field generally spares the organs at risk, but the maximum dose in the
myelon is high (e.g. case 3, carbon ion: 32.9 Gy(RBE)). Two oblique posterior fields resulted in acceptable maximum
doses in the myelon (e.g. case 3, carbon ion: 26.9 Gy(RBE)). The single-field configuration and the two oblique posterior
fields had a small score dispersion (carbon ion: median 66 and 58 (range 62–72 and 40–69)). In cases with topographic
proximity of the organs at risk to the target volume, the single-field configuration scored as well as the three-field
configurations.
Conclusion: In summary, the three-field configurations showed the best dose distributions. A single posterior field
seems to be robust and beneficial in case of difficult topographical conditions and topographical proximity of organs
at risk to the target volume. A setup with two oblique posterior fields is a reasonable compromise between three-field
and single-field configurations.
Keywords: Locally advanced pancreatic cancer, LAPC, Carbon ion, Proton, HIT
Background
Pancreatic cancer patients are still having a dismal progno-
sis. About 277,000 people worldwide die each year due to
this disease [1]. To date resection is considered to be the
only curative treatment. In case of locally advanced unre-
sectable pancreatic cancer (LAPC), neoadjuvant treatment
approaches including combined chemoradiation with gem-
citabine have proven efficacy towards tumor downsizing
and lead to a secondary resectability in approximately 30 %,
even in case of local relapse after primary surgery [2–6].
Modern radiotherapy techniques including IMRT (Inten-
sity-Modulated Radiotherapy) and IGRT (Image-Guided
Radiotherapy) offer more conformal dose distributions and
thus dose to organs at risk (OAR) can be reduced signifi-
cantly. Recently it was shown that IMRT treatment in pan-
creatic cancer patients can provide comparable or less
gastrointestinal toxicity than by conventional radiotherapy
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and therefore contributes to the clinical benefit of the
treated patients, especially when used as dose-escalation
treatment in combination with IGRT [7, 8]. Charged
particle therapy represents an emerging technological
advance in oncology. Particle therapy is characterized by an
inverted depth-dose-curve, which leads to a low dose
deposition within the entry channel and a well-defined high
local dose deposition in the Bragg Peak region [9]. The so
called Spread Out Bragg Peak (SOBP) allows to irradiate
precisely, sparing surrounding normal tissue – both carbon
ion and proton radiotherapy have highly conformal dose
distributions with high dose deposit in the target volume
and an increased sparing of the OARs [9]. High-LET (linear
energy transfer) carbon ion beams are characterized by high
dose deposition in their trajectory. This results in a high
amount of clustered double-strand breaks in the cells‘DNA
(Deoxyribonucleic acid). So, in contrast to photon and
proton beams, carbon ion beams cause an enhanced reduc-
tion in clonogenic survival of pancreatic and also of hepatic
cell lines [10–13]. Carbon ions in particular offer a higher
biological effectiveness due to enhanced and prolonged
DNA damaging and induction of bulky lesions, which can
be translated into higher RBE (Relative Biological Effective-
ness) values [11, 13, 14]. Particle beams are notably appro-
priate in hepatobiliary and pancreatic malignancies, where
radiosensitive normal tissues (e.g. liver, kidneys) are sur-
rounding the target volume [15–17].
There are also encouraging clinical results from Japanese
particle therapy facilities, that have conducted small clinical
trials and gained experience with carbon ion treatment,
using different treatment protocols over the last few years
[16, 18]. Nevertheless, particle therapy of abdominal organs
is very complex. Dose application has to be analyzed
carefully. That’s the reason why the purpose of this study is
to evaluate different plan optimization strategies as a prep-
aration for the clinical practice using active raster scanning
technology [19]. Different proton and carbon ion field
configurations are analyzed with regard to dose distribution
and individual anatomy, using a customized rating scheme.
Patients and methods
Patient characteristics and anatomy criteria
The medical ethics commission of the medical faculty of
Heidelberg consented to this in silico study (S-483/
2011). Five patients with locally advanced, unresectable
pancreatic cancer were included in this study. They were
randomly selected from patients treated with standard
photon plans at our institution. For treatment planning
CT (computed tomography) scans were performed with
and without contrast agent and under free breathing.
Patients were immobilized in supine position.
Over the cranio-caudal direction of the target volume
the minimal distance between two structures was mea-
sured in each horizontal slice, and afterwards the mean
value was calculated. The mean value depends on varia-
tions due to shape and orientation of two structures over
the total target volume extension – the following mea-
sures were calculated:
1. Mean Xmin kidney ri-le = mean minimum distance
between both kidneys
2. Mean Xmin target-kidney le =mean minimum distance
between target and left kidney
3. Mean Xmin target-kidney ri =mean minimum distance
between target and right kidney
4. OAR intersection = intersection between target and
OARs
Patient characteristics and anatomical criteria are sum-
marized in “Table 1”.
Target volume definition
The treatment planning CT scans with the patients’ori-
ginal volumes of photon irradiation have been trans-
ferred to our ion beam treatment planning system. The
original target was made up of a PTV (planning target
volume) including elective nodal irradiation and a boost
volume including the GTV (gross tumor volume) and a
margin of 2–4 mm at the discretion of the responsible
Table 1 Patient characteristics and anatomy criteria
Patient characteristics: Case1 Case2 Case3 Case4 Case5
Gender Male Male Female Male Male
Age at CT scan (years) 71 77 64 67 67
Location Caput Caput Caput Caput/Corpus Caput/Corpus
Target volume (cm3) 332.63 92.31 165.75 224.39 150.35
Anatomical characteristics:
Mean Xmin kidney ri-le (cm) 10.1 9.6 7.5 10.6 7.5
Mean Xmin target-kidney le (cm) 5.4 6.0 3.1 5.3 4.1
Mean Xmin target-kidney ri (cm) 3.2 3.2 3.6 2.5 2.5
OAR-Intersection Large
intestine
Large
intestine
Large intestine,
Stomach/duo-denum,
Liver
Large
intestine
Large intestine,
Stomach/duo-denum,
Liver
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specialist. The boost volumes are defined as the target
volumes in the presented cases.
Treatment Planning System (TPS)
Treatment planning was performed for particle beams
using the raster-scanning technique [19]. Treatment
planning computation was done by TPS Syngo RT Plan-
ning (Siemens, Erlangen, Germany), using the effective
dose calculation model as described by Krämer & Scholz
(Local Effect Model, LEM) [20]. Treatment planning
with proton beams assumes a fixed RBE value of 1.1.
Planning is possible by the use of single field uniform
dose optimization (SBO, Single Beam Optimization) or
multiple field optimization (IMPT, Intensity Modulated
Particle Therapy). Both tools are using intensity modula-
tion, but SBO allows relative weighting factors for each
beam. These beams are optimized independently and
add up to 100 % of the prescribed dose. IMPT integrates
all beams and optimizes simultaneously.
Dose prescription
At our institution a slightly hypofractioned dose regime
has been established for carbon ion irradiation, with a
single dose of 3 Gy(RBE) as described in our forthcom-
ing clinical trial on dose escalated carbon ion therapy for
patients with pancreatic cancer [21]. We chose a fraction
number of 15, representing the second escalation dose
in the above mentioned PHOENIX trial. The calculated
total dose adjusted to the fractionation effect according
to the linear-quadratic model and an α/β-ratio of 2 Gy
would result in approximately 56 Gy(RBE) (BED
2 Gy(RBE)). This dose remains to our opinion realistic
and is effective for both neoadjuvant and definitive
treatment.
Field Setup (FS)
Five different FS at the gantry were considered to be
relevant for this study (Table 2). Field configurations
including three fields use the SBO tool - to minimize
dosimetric uncertainty due to putative anatomical varia-
tions the greatest weight was given to the posterior field
[22]. These five FS were used for all cases – though
slightly adapted to different topography. The gantry
beam angles are described according to the International
Electrotechnical Commission (IEC).
Treatment plans
A total of 50 treatment plans were created – taking
into account 5 FS, both for carbon ions and protons.
The constraints for optimization were put on the
same level. For treatment evaluation the original
structure sets of photon irradiation have been inte-
grated in our TPS, which is why the OAR duodenum
is not available, but integrated in the OAR stomach/
dd.
The criteria and the index for comparison are sum-
marized in “Table 3”. In general, the DVH (Dose-Vol-
ume-Histogram)-parameters were geared to those
constraints, which are significant for toxicity and de-
rived from daily clinical practice. As critical tolerance
doses were not exceeded, we decided to take lower
tolerance limits to better distinguish the different
plans. The OAR criteria of the myelon, the kidneys
and the liver are of equal value; stomach/dd and large
intestine 33 % less; skin 66 % less. So, in comparison
to stomach/dd etc., the criteria value of myelon, kid-
neys and liver is increased. This distinction is due to
the field configurations, for which these organs are
consequently exposed to higher doses. The plans were
compared with each other by using a specific custom-
ized score - the index allocates points amongst the
different plans as follows:
Five FS were compared per case and per radiation
modality (carbon ions, protons). If a plan does not
meet the criteria, it does not receive any points for
this criterion. Among the plans meeting the criteria,
the plan achieving the best value receives the max-
imum number of points. The other plans receive
fewer points in linear intervals (point grading of the
only myelon criterion: 15–12–9–6–3). The cumula-
tive criteria are made up of both target criteria and
OAR criteria. The target criteria represent 32 % of
the score. The OAR criteria get the remaining 68 %
- the relative distribution is identical to the OAR
criteria.
Results
DVH-parameters for proton treatment plans
FS 5 (Fig. 1) has a high dose coverage of the target
with V44 = 98.7 % and 98.6 % for case 3 and 4. The
maximum dose (Dmax) in the myelon, and dose cri-
teria for both kidneys are met in both cases. DVH-
parameters with FS 4 are similar to those with FS 5.
With regard to FS 2 and 3, the target criteria are
satisfied in both cases. Dmax in the myelon is satisfied
in case 3, but narrowly missed in case 4 by both FS
(FS 2 and 3: 25.2 Gy(RBE) and 27.3 Gy(RBE)). In case
3 and 4 FS 3 leads to an increased dose deposition in
both kidneys. In contrast to that, FS 2 is fulfilling the
criteria.
FS 1 (Fig. 1) reaches a high V44 in the target:
97.5 % and 98.1 % (case 3 and 4). The dose criterion
for the myelon cannot be met (case 3 and 4:
32.4 Gy(RBE) and 34.0 Gy(RBE)), but those for both
kidneys can. The mean dose (Dmean) in the right kid-
ney is only half of the dose with FS 5.
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DVH-parameters for carbon ion treatment plans (Fig. 2)
FS 5 (Fig. 2) meets the target criterion V44: 95.8 and
96.2 % for case 3 and 4. Dmax in the myelon is
21.5 Gy(RBE) and 23.2 Gy(RBE) in case 3 and 4. For
both cases, the kidney criteria are satisfied. DVH-
parameters of FS 4 are similar to those of FS 5 for both
cases.
In case 3 FS 3 does not meet the target criterion and
the kidney criteria - but it does in case 4. With regard to
Dmax in the myelon, it is the other way around. FS 2
meets with the target criterion V44 and kidney criteria
in both cases (but for the Dmax). Dmax in the myelon is
24.4 Gy(RBE) and 27 Gy(RBE) in case 4 and 3.
FS 1 (Fig. 2) meets the target criterion V44 for both
cases (96.8 and 95.1 % in case 3 and 4). For case 3 the
target’s volume dose is higher than the one with FS 5.
Dmax in the myelon is 32.9 Gy(RBE) and 34 Gy(RBE) in
case 3 and 4. DVH-parameters in the kidneys (Dmean
(right and left kidney) = 0.4 Gy(RBE) and 2.9 Gy(RBE))
are low in case 3. The same is true for case 4.
Index evaluation (Fig. 3)
Protons: FS 4 and 5 yielded the highest scores for
the OAR criteria. For case 3 FS 1 achieved the same
score as the three-field configurations. Carbon ions:
FS 5 has a wide score dispersion for the target cri-
teria (Median 14 (range 2–34)) and cumulative cri-
teria (Median 74 (range 48–101)). Regarding OAR
criteria, FS 4 and 5 achieved the highest median
scores (58 and 62). Nevertheless, score dispersion is
the smallest for FS 1 (range 46–50). FS 2 also has a
very small score dispersion (range 30–40). On top of
that, in case 3 FS 1 gets almost the same score as the
Table 2 Field setups: characteristics
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three-field configurations, in case 5 FS 1 even exceeds
their score points.
Evaluating the anatomical criteria (Table 1), the
cases 3 and 5 clearly offer a topographic proximity of
the target to the OARs and the OARs to each other.
The mean distance between the right and the left kid-
ney, and the mean distance between the kidneys and
the target itself are small in these cases.
Discussion
Our study focused on treatment planning strategies in pa-
tients with unresectable pancreatic cancer. 50 treatment
plans for proton and carbon ion beams were evaluated.
We developed a score taking into account target volume
coverage and OAR parameters to provide a basis for deci-
sion making during the planning process for this patient
group. The score demonstrates, that for target volume
coverage, all beam angles and combinations provide nearly
equivalent scores with a slight advantage for multiple field
plans.
In summary, a three-field setup achieved consistently
high values throughout the cases. A one-field arrange-
ment with a single posterior field showed in some cases
comparable results and overall very little score disper-
sion. Nevertheless, the maximum doses in the myelon
were thoroughly high. But this field configuration seems
Fig. 1 DVH (Dose-Volume-Histogram) for case 3 and 4 with FS (field setup) 1 and 5: proton
Table 3 Target and OAR criteria
Structure Constraint Maximum points Sum Score
Target: V44≥ 95 % 10 40 Target-Criteria Cumulative-
Criteria
1-V42.75 < 1 % 10
Max < 48.15 Gy(RBE) 10
Min > 40.00 Gy(RBE) 10
Myelon: Max < 24.00 Gy(RBE) 15 15 OAR-Criteria
Each Kidney: V15 < 15.00 % 5 15
D25 < 10.00 Gy(RBE) 5
Mean < 12.00 Gy(RBE) 5
Liver: V20 < 12.50 % 5 15
V10 < 20.00 % 5
Mean < 10.00 Gy(RBE) 5
Stomach/DD: Max < 20.00 Gy(RBE) 5 10
V20 < 15.00 % 5
Large intestine: Max < 20.00 Gy(RBE) 5 10
V35 < 10.00 % 5
Skin: Max Isodose < 50.00 % 5 5
Dreher et al. Radiation Oncology  (2015) 10:237 Page 5 of 9
Fig. 3 Index results for proton and carbon ion treatment plans
Fig. 2 DVH (Dose-Volume-Histogram) for case 3 and 4 with FS (field setup) 1 and 5: carbon ion
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to be of advantage in cases of topographic proximity of
radiosensitive OARs to each other and to the target
volume. The field-setup with two posterior oblique fields
through the kidneys showed satisfying results, was able
to spare the myelon, and score dispersion was quite
small as well.
Particle therapy of abdominal organs is very complex,
as inter- and intraindividual changes in organ motion
and bowel gas movement may have a serious impact on
ion beam dosimetry [22, 23]. Kumagai and colleagues
reported a treatment plan analysis of passive scattered
carbon ion beams at their facility and found out, that
both anterior-posterior and left-right field constellations
caused the highest dose affections (mainly because of
gastrointestinal gas bubbles) [22]. The three-field config-
urations include such fields, which is why they have to
be evaluated critically. Our results also point to more
robustness of a single posterior field compared to three-
field arrangements. In this setting beam paths are prac-
tically not affected by gas fillings in stomach (left-right)
and intestine (anterior-posterior). On top of that, inter-
and intrafractional variations due to breathing may cause
relevant changes in the beam path leading to adverse
effects. Taniguchi and colleagues further analyzed doses
in duodenum and stomach in patients with unresectable
pancreatic carcinoma treated with a five-fraction proto-
col. Results show a decreasing dose to the OARs during
expiration compared to inspiration [24]. The interaction
of beam and organ motion can cause interplay effects
and potentially lead to (unexpected) dose variations in
target structures and thus unwanted normal tissue ex-
posure [25]. However, intra- and inter-fractional changes
are described but not totally understood, which is why
we need re-planning scenarios, especially in scanned ion
beam treatment, where slight changes may result in
significant dose variations [22–24, 26]. In general, we are
referring to Japanese experiences in ion beam therapy of
LAPC. But one has to be clear about the fact, that irradi-
ation was performed by the use of scattered ion beam
therapy. Our department made investigations in robust-
ness in scanned ion beam therapy, which we can rely on.
Batista et al. has presented data about pancreatic cancer,
that supported our results. A single posterior field and
two oblique posterior fields show good results in case of
robustness [27]. On top of that Richter et al. has made
investigations in the topic of robustness of ion beam
irradiation of liver tumors. The group was able to show,
that fractionation is a potential tool to reduce dose inho-
mogenity by interplay effects [28, 29]. That is one of the
reasons why our PHOENIX trial has dose escalation
steps starting with 12 fractions [21].
In out treatment plan computations doses to OARs
were thoroughly uncritical. But distinct field setups lead
to different risk profiles. Whereas posterior fields deposit
higher doses to the myelon and partial volumes of the
kidneys, right lateral fields are surely affecting partial
liver volumes. Higher doses in intestinal structures were
found when left lateral and anterior fields were used
(three-field configurations). Even though only small sub-
volumes received remarkable doses, this could theoretic-
ally result in clinically relevant complications. The ex-
perience on comparable dose protocols with intestinal
structures in close proximity to the target volume is
based on carbon ion therapy of sacral chordoma and
locally recurrent rectal cancer, where no higher gastro-
intestinal toxicities were recorded [30, 31].
The single posterior field setup is of major concern,
because of a steep RBE-increase at the distal end of the
SOBP, which could result in unexpected high doses to
the small intestine ventrally of the pancreatic tumor.
Calculated doses to intestines were in the range of toler-
ance. With regard to the DVH, the single posterior field
can spare most of the OARs. High doses in the myelon
were calculated, but did not exceed general QUANTEC
(Quantitative Analyses of Normal Tissue Effects in the
Clinic) dose constraints [32].
Nevertheless, tolerance doses of the OARs are not well
defined for carbon ion irradiation and are extrapolated
from photon-based data as long as no new dose-volume
thresholds are defined. An important limitation of the
LEM-based TPS is also the underlying biological dataset.
According to our current clinical practice we do not dif-
ferentiate the radiobiological characteristics of normal
tissue and tumor during treatment plan optimization.
Experience with carbon ion beams based on newer bio-
logical optimized LEM-algorithms within the TPS are
only theoretical and not debated in this work [33].
Topographical influence and advantage of the single-
field configuration is mainly expressed by carbon ion
beams. It is likely that the proton beams are at a disad-
vantage due to their wider lateral dose gradient [9]. Due
to this beam broadening, especially with deeper located
targets, smearing of the dose distribution possibly results
in plans inferior to advanced photons. Basically, a direct
comparison between carbon ion and proton beams
could be drawn but this may not be useful, as we are
currently still working with an earlier version of LEM
[34]. Therefore the dose in the proximal part of the
beam channel is rather overestimated and the dose in
the target itself is underestimated as recently demon-
strated by Grun and co-workers with an improved ver-
sion of the local effect model (LEM IV) [35]. Carbon ion
radiation would result in more beneficial dose distribu-
tions both in the target and OARs than shown in the
presented data.
Nonetheless, our study was able to present possible
field setups and evaluated them by the use of a custom-
ized score. With reference to our results, particle therapy
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of pancreatic cancer is possible by the use of all 5 field
setups. Distinct topographical conditions should be taken
into account.
Future work of our group will focus on even more
differentiated radiobiological-based treatment planning,
which includes different α/β ratios for normal and target
tissues.
Conclusion
In summary, field configurations with three fields showed
the best dose distributions – for both carbon ion beams
and proton beams. Nevertheless, three-field configurations
are highly influenced by gastrointestinal variations. A
single posterior field deposits high doses in the myelon,
but seems to be the most robust one and showed good
results for difficult and varying topographical conditions.
A setup with two oblique posterior fields generated repro-
ducible results and can be set as a reasonable compromise
between three fields and one field configurations.
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